The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

Condition studied

Primary Central Nervous System Lymphoma

Investigational medicinal product(s)

Eligibility

Primary endpoint

The proportion of participants in whom the cancer gets worse, or who passed away, within 12 months after getting liso-cel.

Endpoint detail

The time it takes for the cancer to worsen, The time it takes for the participant to start a new cancer treatment, The time it takes for the participants to pass away, after they enroll into the study;, The proportion of participants with no detectable signs of cancer, The proportion of participants with improvement in signs (complete and partial responses), at any time after getting the liso-cel treatment and before the cancer gets worse, they start a new cancer treatment, or the study ends, How long the responses last, How the treatment affects the participants' quality of life, What kinds of health problems participants experience during the study, how severe they are, and how often they happen, How the treatment affects participants’ ability to think and use their memory measured using two simple tests that look at memory, attention, and thinking speed.